Abstract: The present study was aimed at the development and evaluation of Desvenlafaxine fast dissolving tablets (FDTs) using super disintegrants by the direct compression method. Desvenlafaxine is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the treatment of major depressive disorder. Fast dissolving tablets were formulated to improve patient compliance, particularly in geriatric and dysphagic patients, by providing rapid tablet disintegration and faster drug release.  Among the formulations, F8 exhibited the best performance, showing the shortest disintegration and wetting times along with the highest cumulative drug release of 99.65% within the specified dissolution period. Drug release kinetic analysis demonstrated that the optimized formulation best fitted the Korsmeyer–Peppas model, indicating diffusion-controlled drug release. Accelerated stability studies performed according to ICH guidelines showed that the optimized formulation remained stable over a period of three months without significant changes in its physical properties, drug content, or dissolution profile. In conclusion, the optimized Desvenlafaxine fast dissolving tablet prepared by the direct compression method demonstrated excellent tablet characteristics, rapid drug release, and satisfactory stability. The developed formulation has the potential to enhance patient compliance and provide a faster onset of therapeutic action, making it a promising alternative to conventional oral tablets for the treatment of major depressive disorder.